Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, November 11 at 2:00 PM ET

Register Free →

This Subcontract opportunity from Department Of Veterans Affairs was posted on September 18, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Pharmaceutical Packaging and Labeling Services

Closed
Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

AI Contract Overview

Show more

This subcontract for Pharmaceutical Packaging and Labeling Services involves the packaging and labeling of Glipizide Tablets to support prime contractors delivering pharmaceutical supplies to the VA, DoD, BOP, IHS, and FHCC. The scope of work includes bottling, blister packing, and the application of labels that meet specific VA and DoD requirements using specialized pharmaceutical machinery. All operations must strictly adhere to FDA cGMP standards and the requirements outlined in Section 5 of the contract scope to ensure the tablets are ready for final shipment. This opportunity is issued by Nac Pharmaceuticals under the Department of Veterans Affairs, with a response deadline of October 8, 2026.

General Info

Nac Pharmaceuticals subcontract for Glipizide packaging and labeling services following FDA cGMP standards.

NAICS

339999 - All Other Miscellaneous Manufacturing

Place of Performance

IL

Set-Aside

NONE

Documents

This scope was carved out of 36E79726R0031_1.

The full solicitation package (4 documents), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

6505--Glipizide Tablets

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PhaseClosed
Posted

subcontract

Response Deadline

Deadline has passed

Submission Closed

Find active opportunities like this

Get full access to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

Show more
AgencyDepartment Of Veterans Affairs → Nac Pharmaceuticals (36E797)
ContactsNo contacts available
OfficeN/A
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Performs packaging and labeling of Glipizide Tablets for prime contractors delivering pharmaceutical supply contracts to the VA, DoD, BOP, IHS, and FHCC. Executes blister packing, bottling, and application of labels meeting VA/DoD requirements using pharmaceutical packaging machinery. Must comply with FDA cGMP standards and Section 5 Scope of Contract requirements. Delivers packaged and labeled tablets ready for shipment.

More opportunities from Department Of Veterans Affairs → Nac Pharmaceuticals (36E797)

Same awarding agency

NAICS: 325412
Federal
6505--Latanoprost Ophthalmic Solution (VA-27-00006027)
Solicitation # 36E79727R0039
The Department of Veterans Affairs is soliciting proposals for the procurement of Latanoprost 0.005% Ophthalmic Solution to ensure an uninterrupted supply for the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. This unrestricted commercial item procurement is structured into two groups, with one award made in the aggregate for either Group I (single bottles) or Group II (single and bulk cartons). The resulting contract will consist of a one-year base period followed by four pre-priced one-year option periods. Distribution will be managed through the VA and DoD Pharmaceutical Prime Vendor Programs, requiring the contractor to deliver supplies to designated distribution centers based on business-to-business agreements. Award will be granted based on the lowest evaluated price among proposals that meet all non-cost acceptability standards. Offerors must provide a unique 11-digit NDC number and adhere to the American Academy of Ophthalmology’s uniform color-coding system for caps and labels. Strict compliance with FDA current Good Manufacturing Practice standards is required, and offerors must certify they possess the necessary NDA, ANDA, or BLA approvals. Additionally, products must meet rigorous barcoding and serialization requirements under the Drug Supply Chain Security Act, including the use of GS-1 data matrix codes. Proposals must be submitted by November 17, 2026, and must include a 0.5% cost recovery fee embedded in the pricing.
Pharmaceutical Preparation Manufacturing

POSTED

9 days ago

DEADLINE

in 9 days
View Details

Earlier notices in this NAICS code

Posted before this notice, open and closed

Find Active Opportunities Like This

Get AI-powered intelligence on the opportunities still open

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Miguel
Hillary
Keith Deutsch
Christine

Join 750+ contractors already using CLEATUS